BioWorld

Jan. 24, 2003

CAG Repeats Multiply Glutamine, Axis Of Eight Or More Neuronal Diseases CR Agent Might Treat

Nabi-HB Product Granted Priority Review In Liver Transplant Setting

Antigenics Raises $62M Publicly To Fund Development Programs

Other News To Note

Blockbuster Deal In England: CAT Acquiring OGS For $177M

Cambridge Antibody Technology Group plc plans to acquire Oxford GlycoSciences plc in an all-share deal valuing OGS at £109.6 million (US$177 million). The deal would create a company with a £260 million cash pile and a market capitalization of around £289 million. (BioWorld Today) Read More

Amgen Posts Earnings Gains, Updates Two Pipeline Programs

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...